Immune Pharmaceuticals (IMNP) vs. Bristol-Myers Squibb Company (BMY) Critical Survey
Immune Pharmaceuticals (NASDAQ: IMNP) and Bristol-Myers Squibb Company (NYSE:BMY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitabiliy, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.
Volatility and Risk
Immune Pharmaceuticals has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb Company has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Bristol-Myers Squibb Company pays an annual dividend of $1.56 per share and has a dividend yield of 2.9%. Immune Pharmaceuticals does not pay a dividend. Bristol-Myers Squibb Company pays out 54.2% of its earnings in the form of a dividend. Bristol-Myers Squibb Company has raised its dividend for 7 consecutive years.
This is a breakdown of current ratings and target prices for Immune Pharmaceuticals and Bristol-Myers Squibb Company, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Bristol-Myers Squibb Company||1||10||9||0||2.40|
Immune Pharmaceuticals currently has a consensus price target of $3.00, indicating a potential upside of 13.20%. Bristol-Myers Squibb Company has a consensus price target of $62.35, indicating a potential upside of 14.37%. Given Bristol-Myers Squibb Company’s higher possible upside, analysts clearly believe Bristol-Myers Squibb Company is more favorable than Immune Pharmaceuticals.
This table compares Immune Pharmaceuticals and Bristol-Myers Squibb Company’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Bristol-Myers Squibb Company||24.22%||31.86%||14.77%|
Institutional & Insider Ownership
60.4% of Immune Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Bristol-Myers Squibb Company shares are held by institutional investors. 6.7% of Immune Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Bristol-Myers Squibb Company shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Immune Pharmaceuticals and Bristol-Myers Squibb Company’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Immune Pharmaceuticals||N/A||N/A||-$14.27 million||($14.60)||-0.18|
|Bristol-Myers Squibb Company||$19.97 billion||4.50||$6.89 billion||$2.88||18.93|
Bristol-Myers Squibb Company has higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb Company, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb Company beats Immune Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.